Clinical Trials
A clinical trial evaluated exposure parameters associated with 3-phenoxybenzoic acid by measuring biomarker levels related to oxidative stress and inflammation in human cohorts. Sponsored by academic and governmental entities, specifically the Cyprus University of Technology and the European Commission, this completed investigation was conducted without a traditional interventional phase designation. Overall, clinical research regarding this compound focuses on biomonitoring environmental and dietary influences on physiological stress responses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02998203 | Completed | Oxidative Stress|Inflammation |
Cyprus University of Technology|European Commission |
2017-01-03 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- 3-Phenoxybenzoic acid Solubility in DMSO
- 3-Phenoxybenzoic acid Stock Solution
- 3-Phenoxybenzoic acid Storage
- 3-Phenoxybenzoic acid Stability
- 3-Phenoxybenzoic acid Molecular Weight
- 3-Phenoxybenzoic acid SMILES
- 3-Phenoxybenzoic acid CAS Number
- 3-Phenoxybenzoic acid Chemical Structure (2D and 3D)
- 3-Phenoxybenzoic acid SDS|MSDS